Group 1 - The core point of the article is that Wanfu Biology announced the approval of its investment in Saiweisen Technology's "Cervical Cell Digital Pathology Image Assisted Diagnosis Software," marking a significant milestone in the field of cervical cytology with the first AI-assisted diagnosis Class III product registration in the country [1] - The AI-assisted reading of slides significantly enhances diagnostic efficiency and accuracy, providing more precise treatment plans for patients [1] - Saiweisen is committed to offering a comprehensive solution for intelligent pathology AI-assisted diagnosis and aims to continue innovating in the pathology AI field, promoting the digital transformation of the industry [1]

Core Viewpoint - The company has made significant advancements in the AI sector, particularly in the field of cervical cytology, with the approval of an AI-assisted diagnostic software, marking a milestone in digital pathology [2] Company Summary - Wanfu Biology (300482.SZ) announced on July 30 that its investment in Saiweisen Technology's "Cervical Cell Digital Pathology Image Assisted Diagnosis Software" has received formal approval, becoming the first AI-assisted diagnostic Class III product registration in the national cervical cytology field [2] - This approval signifies a new milestone for the "Digital Pathology + AI Assistance" model, which enhances diagnostic efficiency and accuracy through AI-assisted slide reading, providing more precise treatment plans for patients [2] - Saiweisen is committed to offering a comprehensive solution for intelligent pathology AI-assisted diagnosis, and with the company's support, it will continue to deepen its focus on the pathology AI field, driving the development and application of more innovative technologies [2] Industry Summary - The approval of the AI-assisted diagnostic software is expected to contribute to the digital transformation of the pathology industry, providing higher quality and smarter pathology solutions for doctors and patients [2]